Frontiers in Endocrinology最新文献

{"title":"The expression of autophagy-related gene CXCL12 in endometriosis associated ovarian cancer and pan-cancer analysis.","authors":"Mingwei Yuan, Sijing Chen, Zelan Liao, Kana Wang","doi":"10.3389/fendo.2025.1450892","DOIUrl":"10.3389/fendo.2025.1450892","url":null,"abstract":"<p><strong>Background: </strong>Endometriosis-associated ovarian cancer (EAOC), an aggressive form of malignant ovarian neoplasm with origins in endometriosis (EM), has risen to prominence recently. Despite extensive investigation, the precise pathophysiology remains elusive.This article explores new autophagy-related DEG genes between EM and EAOC, and investigates CXCL12's expression and prognostic relevance across pan-cancer.</p><p><strong>Methods: </strong>From Gene Expression Omnibus (GEO), we retrieved gene sequencing data to uncover DEGs. We carried out enrichment analysis, PPI network construction and explored CXCL12's multi-database expression and prognostic significance employing the analytical tools of ONCOMINE, PrognoScan, GEPIA, and Kaplan-Meier Plotter. Subsequently, assessing the relationship between CXCL12 expression and immune presence in cancer utilizing GEPIA and TIMER. Lastly, CXCL12, IL17, STAT3, and FOXP3 protein expressions were determined through immunohistochemistry analysis in EAOC, EM, and normal endometrial tissues.</p><p><strong>Results: </strong>Two DEGs were discovered and enrichment analysis indicated virus-cytokine/receptor interactions, chemokine signaling, and cytokine-cytokine receptor interplay as pivotal in EAOC. Notably, cancerous tissues exhibited reduced CXCL12 levels compared with non-malignant tissues across cancers. CXCL12, IL17, STAT3, Th17/Treg ratio, and FOXP3 expressions were also lower in EAOC than EM and normal tissues. Additionally, CXCL12 expression was related to stage, survival, immune subtype, and molecular classification across cancers.</p><p><strong>Conclusions: </strong>In conclusion, our study implicates CXCL12 and altered Th17/Treg balance in progression from EM to EAOC. CXCL12 emerges as a predictive marker for cancer progression across various tumors and is associated with inflammatory response.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1450892"},"PeriodicalIF":3.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of hormone therapies for treating adenomyosis-associated pelvic pain: a systematic review and network meta-analysis of randomized controlled trials.","authors":"Andrea Etrusco, Vittorio Agrifoglio, Antonio D'Amato, Vito Chiantera, Antonio Simone Laganà, Joe Haydamous, Luigi Cobellis, Pasquale De Franciscis, Silvia Vannuccini, Harald Krentel, Antoine Naem, Gaetano Riemma","doi":"10.3389/fendo.2025.1571727","DOIUrl":"10.3389/fendo.2025.1571727","url":null,"abstract":"<p><strong>Background: </strong>To date, there are no clear guidelines available on the treatment of adenomyosis-associated pelvic pain (AAPP); however, numerous hormonal treatments (HTs) are currently being used off-label. We conducted a systematic review and network metanalysis with the aim of assessing the efficacy and safety of HTs to reduce AAPP and ranking the available options.</p><p><strong>Methods: </strong>MEDLINE, LILACS, EMBASE, Scielo.br, PROSPERO, Cochrane Library, conference proceedings, and international registries were searched with no time, region, or language restrictions. Randomized controlled trials that analyzed AAPP in women undergoing HTs were deemed suitable.</p><p><strong>Results: </strong>Six studies (563 women affected by adenomyosis) were included. At 3 months, women who received a placebo or a levonorgestrel-based intrauterine system (LNG-IUS) experienced more AAPP than those who received dienogest [mean difference of visual analog scale (VAS) pain scores (MD) 4.10 (95% CI 0.49 to 7.71); high evidence; MD 3.05 (95% CI 0.45 to 5.65); high evidence]. At 6 months, women who received dienogest experienced significantly less AAPP compared to those who received combined oral contraceptives [MD -2.85 (95% CI -5.30 to -0.39); moderate evidence], while the prevalence of AAPP was higher among those who received a LNG-IUS than those who received dienogest [MD 1.79 (95% CI 0.06 to 3.53); low evidence].</p><p><strong>Conclusion: </strong>Dienogest seems to be the most effective HT for AAPP. However, although rare, it is also related to more adverse effects compared to other HTs.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier CRD42024535472.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1571727"},"PeriodicalIF":3.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential compensatory mechanism for cognitive impairment in type 2 diabetes and prediabetes: altered structure-function coupling.","authors":"Weiye Lu, Xuan Huang, Die Shen, Kun Wang, Jiahe Wang, Ziyu Diao, Shijun Qiu","doi":"10.3389/fendo.2025.1491377","DOIUrl":"10.3389/fendo.2025.1491377","url":null,"abstract":"<p><strong>Background: </strong>Structure-function (SC-FC) coupling may be more sensitive to detecting changes in the brain than any single modality. The aim of this study was to investigate the effects of SC-FC coupling changes on cognition and their interactions in patients with prediabetes and type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>A total of 493 participants (119 with normal glucose metabolism (NGM), 125 with prediabetes, and 249 with T2DM) were included in the study. Diffusion-weighted MRI and resting state functional MRI data were used to quantify SC-FC coupling. General linear model and linear regression analysis were used to evaluate the relationship between glucose metabolism, SC-FC coupling, and cognition. Mediation models were used to evaluate the mediating role of regional SC-FC coupling between diabetes-related measures and cognition.</p><p><strong>Results: </strong>The regional coupling strength of SC-FC varied greatly in different brain regions, but was strongest in the ventral attention and somatmotor network areas. Compared with NGM patients, T2DM patients had higher SC-FC coupling in the default mode network but lower SC-FC coupling in the limbic network. In addition, fasting glucose and HbA_1c were associated with weaker SC-FC coupling in the limbic network, fasting insulin with higher SC-FC coupling in the limbic network, and HbA_1c with higher SC-FC coupling in the dorsal attention network. Furthermore, through mediated models we found that SC-FC coupling in the limbic network suppressed the association between diabetes-related measures and cognition.</p><p><strong>Conclusion: </strong>T2DM and diabetes-related measures were associated with abnormal SC-FC coupling of the limbic network. The recombination of SC-FC coupling relationships in the limbic network may indicate a potential compensatory mechanism for cognitive decline that begins in prediabetes.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1491377"},"PeriodicalIF":3.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between pan-immune-inflammation value and dyslipidemia in the United States population.","authors":"Yu Yan, Shanshan Jia, Xingwei Huo, Lu Liu, Lirong Sun, Shuangliang Ma, Xiaoping Chen","doi":"10.3389/fendo.2025.1518304","DOIUrl":"10.3389/fendo.2025.1518304","url":null,"abstract":"<p><strong>Object: </strong>To investigate the possible association between pan-immune-inflammation value (PIV) and dyslipidemia.</p><p><strong>Methods: </strong>This cross-sectional study used the data obtained from National Health and Nutrition Examination Survey (NHANES). The independent variable used the logarithmic form of PIV-log2 (PIV). The definition of dyslipidemia was based on the National Cholesterol Education Program standards. Weighted multivariate logistic regression analyses, the restricted cubic spline (RCS) and threshold effect analysis were explore the association between PIV and dyslipidemia. Stratified analyses were used to identify potential associations with other covariates. The receiver operating characteristic (ROC) curve was constructed compared to systemic immune-inflammation index (SII).</p><p><strong>Results: </strong>6,821 participants were included, of whom 47% were male and 77% had dyslipidemia. After adjusting for all confounders, PIV and dyslipidemia had an significantly positive association (OR (95%CI): 1.13 (1.01-1.25); <i>P =</i> 0.03). Compared to participants with lowest quartile (Q1) of PIV, participants with the highest quartile (Q4) had a significantly higher risk of dyslipidemia (OR (95%CI): 1.37 (1.05-1.80); <i>P =</i> 0.022). The RCS curve showed an inverted J-shaped relationship between PIV and dyslipidemia (<i>P</i>-nonlinear = 0.0415, <i>P</i>-overall < 0.001). The threshold effect analysis revealed that the inflection point was 9.192. Stratified analyses showed that age and BMI modified the PIV-dyslipidemia relationship (<i>P</i> for interaction < 0.05). The ROC curve found that compared with SII, PIV had a similar predictive value (area under curve (AUC): 0.566 vs 0.558; <i>P</i> = 0.073).</p><p><strong>Conclusion: </strong>This study discovered that PIV had a significantly positive relationship with dyslipidemia, especially in young and overweight individuals.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1518304"},"PeriodicalIF":3.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status, trend changes, and future predictions of the disease burden of type 1 diabetes kidney disease in global and China.","authors":"Qinghua Yang, Li Jin, Mingwei Luo, Shiwei Xie","doi":"10.3389/fendo.2025.1559363","DOIUrl":"10.3389/fendo.2025.1559363","url":null,"abstract":"<p><strong>Objective: </strong>This study analyzes the global and China trends in the prevalence, disease burden, and future projections of Type 1 Diabetic Nephropathy (T1DN) over the past three decades, providing data to inform public health policies and clinical interventions.</p><p><strong>Methods: </strong>Data from the Global Burden of Disease (GBD) 2021 database were used to analyze the incidence, prevalence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) of T1DN globally and in China from 1990 to 2021. Trend analysis was conducted using R and Joinpoint software, and the ARIMA model was applied to predict future trends in T1DN prevalence for the next 20 years. A significance level of p<0.05 was applied.</p><p><strong>Results: </strong>Globally, deaths from T1DN increased from 49,300(95% CI: 39,088-61,207) in 1990 to 94,020 (95% CI: 71,456-119,984)in 2021, with the age-standardized mortality rate remaining stable. DALYs rose from 2,227,518(95% CI: 1,835,372-2,679,207) in 1990 to 3,875,628 (95% CI: 3,062,395-4,845,503) in 2021, though the age-standardized rate slightly decreased. In China, the mortality rate declined significantly, and DALYs decreased, with the age-standardized DALYs dropping from 80.915/100,000(95% CI: 65.121-98.391)to 47.953/100,000(95% CI: 36.9-60.734). Globally, both incidence and prevalence increased, with global incidence reaching 95,140(95% CI: 82,236-111,471) cases and prevalence rising to 6,295,711 (95% CI: 5,459,693-7,114,345)cases. In China, incidence showed a declining trend, but prevalence continued to rise. The ARIMA model forecasts global incidence will reach 115,000 cases, with prevalence reaching 7,000,000 by 2041. In China, incidence is expected to stabilize, while prevalence may increase to approximately 2,500,000 cases.</p><p><strong>Conclusion: </strong>The burden of T1DN is rising globally, especially in terms of prevalence, while China has made progress in reducing mortality and disease burden. However, challenges remain in chronic disease management. Over the next 20 years, global prevalence is projected to continue increasing, while China's prevalence may stabilize. Targeted interventions for different age groups and genders will be essential in reducing the T1DN burden.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1559363"},"PeriodicalIF":3.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of diabetic retinopathy and its predictors among adult patients with diabetes in Ethiopia: a frailty model.","authors":"Tagese Yakob, Awoke Abraham, Begidu Yakob, Mesfin Manza Jaldo","doi":"10.3389/fendo.2025.1462210","DOIUrl":"10.3389/fendo.2025.1462210","url":null,"abstract":"<p><strong>Background: </strong>Diabetic retinopathy (DR) is becoming a more widespread public concern worldwide, leading to visual impairments. It has become the leading cause of blindness among working-age adults globally, despite established treatments that can reduce the risk by 60%.</p><p><strong>Objective: </strong>This study aimed to determine the incidence of diabetic retinopathy and its predictors among adult patients with diabetes in public hospitals in Central and Southern Ethiopia.</p><p><strong>Methods: </strong>A hospital-based follow-up study was conducted in selected public hospitals in Central and Southern Ethiopia. A total of 376 participants of newly diagnosed adult diabetes were enrolled from 2015-2023 and the follow-up the date was from date of enrolment to the development of events. The data were collected by reviewing their records and entered in Epi-data version 4.6.0.2 and exported to STATA version 14 for analysis. Descriptive statistics of the variables were obtained. The Weibull model with gamma frailty distribution was fitted. Bivariable and multivariable analyses were done, and variables with a p-value less than 0.05 and a corresponding 95% confidence interval in the final model were used. The model of adequacy was checked.</p><p><strong>Results: </strong>376 adult diabetic patient records were reviewed with the mean baseline age (± standard deviation) of 34.8±10 years. The univariate frailty was statistically significant (Theta=0.236 (0.131, 0.496)). A total of 376 adult patients with diabetes were followed for 682.894 person-years. Overall, an incidence rate of 14.06/100 person-years. Proteinuria (AHR = 2.21: 95% CI: 1.45, 3.57), cardiovascular disease (AHR = 2.23: 95% CI: 1.34, 4.03), and type II DM (AHR = 2.87: 95% CI: 1.30, 6.13) were identified as significant predictors of diabetic retinopathy.</p><p><strong>Conclusion: </strong>Overall incidence rate of diabetic retinopathy was high. The most effective way to protect our vision from diabetic retinopathy is to manage diabetes effectively and offer support to high-risk individuals with diabetes. Therefore, healthcare professionals and relevant health authorities should target on addressing these factors in their initiatives to prevent diabetic retinopathy in diabetic patients.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1462210"},"PeriodicalIF":3.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in diet-induced MASLD - are female mice naturally protected?","authors":"Jana Meyer, Ana Mendes Teixeira, Sandy Richter, Dean P Larner, Asifuddin Syed, Nora Klöting, Madlen Matz-Soja, Susanne Gaul, Anja Barnikol-Oettler, Wieland Kiess, Diana Le Duc, Melanie Penke, Antje Garten","doi":"10.3389/fendo.2025.1567573","DOIUrl":"10.3389/fendo.2025.1567573","url":null,"abstract":"<p><p>Males suffer more often from profibrotic changes in liver than females. The underlying mechanism for this sex difference in the prevalence and manifestation of Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) is not yet completely known. We studied male and female mice that were induced to develop MASLD by consuming a \"fast food\" diet (FFD) and assessed metabolic phenotype as well as liver histology and compared them with mice fed with a matched control diet (CD). Our aim was to check for sex-specific differences in MASLD development in a mouse model of diet-induced profibrotic changes in the liver. Our results demonstrate a clear difference in body weight, fat distribution and changes in liver tissue for male and female mice fed with FFD. We found that female mice stored lipids mainly in subcutaneous and visceral adipose tissue while males increased ectopic lipid accumulation in the liver which resulted in hepatomegaly and increased <i>transforming growth factor β 1</i> (<i>Tgfb1</i>) and <i>collagen I</i> (<i>Col1a1</i>) expression concomitant to fibrosis development. This was absent in female mice. Analysis of estrogen receptor -α <i>(Esr1)</i> and -β <i>(Esr2)</i> expression revealed an upregulation of <i>Esr2</i> in livers of male FFD-fed mice whereas in female liver tissue a higher expression in <i>Esr1</i> could be observed. This study supports <i>Esr1</i> and <i>Esr2</i> as potential targets to reverse negative effects of diet-induced profibrotic changes in the liver.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1567573"},"PeriodicalIF":3.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antagonistic effects of smoking and maternal glycemia on fetal growth: a retrospective study among 13,958 pregnant French women.","authors":"Emmanuel Cosson, Lionel Carbillon, Sopio Tatulashvili, Hélène Bihan, Eric Vicaut, Ines Barka, Sara Pinto, Imen Rezgani, Mohamed Zerguine, Jean-Jacques Portal, Marion Fermaut, Jardena J Puder, Amélie Benbara","doi":"10.3389/fendo.2025.1527358","DOIUrl":"10.3389/fendo.2025.1527358","url":null,"abstract":"<p><strong>Introduction: </strong>Smoking and hyperglycemia first diagnosed during pregnancy (H1inP) have opposing effects on fetal growth. The aim of this study was to explore adverse pregnancy outcomes, particularly fetal growth, according to the smoking and H1inP status.</p><p><strong>Methods: </strong>We included 13,958 women from a large French dataset (2012-2018). Using multivariable regression analyses, we retrospectively evaluated the risk of large-for-gestational-age (LGA) babies and other adverse outcomes according to the H1inP and smoking status in four groups: no H1inP/non-smoker (group A: <i>n</i> = 10,454, 88.2%), no H1inP/smoker (group B: <i>n</i> = 819, 5.9%), H1inP/non-smoker (group C: <i>n</i> = 2,570, 18.4%), and H1inP/smoker (group D: <i>n</i> = 115, 0.8%).</p><p><strong>Results: </strong>The rates of LGA were 8.9%, 4.0%, 14.6%, and 8.7% in groups A, B, C, and D, respectively (global ANOVA <i>p</i> < 0.0001, factor H1inP <i>p</i> = 0.0003, factor smoking <i>p</i> = 0.0002, and interaction <i>p</i> = 0.48). After adjustment for potential confounders including age, body mass index, employment, ethnicity, parity, hypertension before pregnancy, gestational weight gain, and alcohol and drug consumption, H1inP was associated with a higher risk [odds ratio (OR) = 1.50, 95% confidence interval (95%CI) = 1.30-1.74] and smoking with a lower risk (OR = 0.35, 95%CI = 0.25-0.50) of LGA. In addition, H1inP was associated with a lower total gestational weight gain and a lower rate of small-for-gestational-age (SGA) babies, but higher rates of hypertensive disorders and more frequent caesarean sections and admissions in the neonatal intensive care unit. Smoking was associated with higher rates of SGA, including severe SGA (<3rd centile), and this despite a higher total gestational weight gain. Smoking increased the risk of hypertensive disorders only in women with H1inP.</p><p><strong>Discussion: </strong>Smoking among women with H1inP could mask the risk of maternal hyperglycemia for LGA babies. This could provide a false sense of security for women with H1inP who smoke, particularly when assessing for LGA alone, but these women still face other risks to their health, such as hypertensive disorders and the health of the fetus.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1527358"},"PeriodicalIF":3.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing a machine learning-based predictive model for levothyroxine dosage estimation in hypothyroid patients: a retrospective study.","authors":"Tran Thi Ngan, Dang Huong Tra, Ngo Thi Quynh Mai, Hoang Van Dung, Nguyen Van Khai, Pham Van Linh, Nguyen Thi Thu Phuong","doi":"10.3389/fendo.2025.1415206","DOIUrl":"10.3389/fendo.2025.1415206","url":null,"abstract":"<p><p>Hypothyroidism, a common endocrine disorder, has a high incidence in women and increases with age. Levothyroxine (LT4) is the standard therapy; however, achieving clinical and biochemical euthyroidism is challenging. Therefore, developing an accurate model for predicting LT4 dosage is crucial. This retrospective study aimed to identify factors affecting the daily dose of LT4 and develop a model to estimate the dose of LT4 in hypothyroidism from a cohort of 1,864 patients through a comprehensive analysis of electronic medical records. Univariate analysis was conducted to explore the relationships between clinical and non-clinical variables, including weight, sex, age, body mass index, diastolic blood pressure, comorbidities, food effects, drug-drug interactions, liver function, serum albumin and TSH levels. Among the models tested, the Extra Trees Regressor (ETR) demonstrated the highest predictive accuracy, achieving an R² of 87.37% and the lowest mean absolute error of 9.4 mcg (95% CI: 7.7-11.2) in the test set. Other ensemble models, including Random Forest and Gradient Boosting, also showed strong performance (R² > 80%). Feature importance analysis highlighted BMI (0.516 ± 0.015) as the most influential predictor, followed by comorbidities (0.120 ± 0.010) and age (0.080 ± 0.005). The findings underscore the potential of machine learning in refining LT4 dose estimation by incorporating diverse clinical factors beyond traditional weight-based approaches. The model provides a solid foundation for personalized LT4 dosing, which can enhance treatment precision and reduce the risk of under- or over-medication. Further validation in external cohorts is essential to confirm its clinical applicability.</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1415206"},"PeriodicalIF":3.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: High glucose induced HIF-1α/TREK1 expression and myometrium relaxation during pregnancy.","authors":"","doi":"10.3389/fendo.2025.1589452","DOIUrl":"https://doi.org/10.3389/fendo.2025.1589452","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3389/fendo.2023.1115619.].</p>","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"16 ","pages":"1589452"},"PeriodicalIF":3.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}